Epilepsy in early onset Alzheimer’s disease
| Autor: | Olivier Aron, Sarah Haoudy, Louis Maillard, Salomé Puisieux, Lucie Hopes, Thérèse Rivasseau Jonveaux, Jonathan I. Epstein, Louise Tyvaert |
|---|---|
| Přispěvatelé: | Service de neurologie [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Laboratoire lorrain de psychologie et neurosciences de la dynamique des comportements (2LPN), Université de Lorraine (UL), Centre d'investigation clinique [Nancy] (CIC), Université de Lorraine (UL)-Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre de Recherche en Automatique de Nancy (CRAN), Centre National de la Recherche Scientifique (CNRS)-Université de Lorraine (UL) |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
Pediatrics medicine.medical_specialty Comorbidity Neuropsychological Tests [SPI.AUTO]Engineering Sciences [physics]/Automatic 03 medical and health sciences Epilepsy 0302 clinical medicine Alzheimer Disease Seizures medicine Humans Cognitive Dysfunction Early-onset Alzheimer's disease Prospective Studies Age of Onset Aged 030304 developmental biology 0303 health sciences business.industry General Neuroscience Electroencephalography General Medicine Middle Aged medicine.disease 3. Good health Psychiatry and Mental health Clinical Psychology Anticonvulsants Female Geriatrics and Gerontology business 030217 neurology & neurosurgery |
| Zdroj: | Journal of Alzheimer's Disease Journal of Alzheimer's Disease, IOS Press, In press, pp.Pre-Press. ⟨10.3233/JAD-210681⟩ |
| ISSN: | 1387-2877 |
| DOI: | 10.3233/JAD-210681⟩ |
| Popis: | International audience; Background: Epilepsy seems to be an important comorbidity in patients with early onset Alzheimer’s disease (EOAD). Currently, seizures are still underestimated in this population. However, seizures may interact with AD evolution with possible acceleration of cognitive decline. Objective: To better define the epileptic disorders observed in patients with EOAD. Methods: All patients diagnosed as EOAD in our hospital between 2013 and 2019 with positive CSF biomarkers for AD were selected. The usual follow-up was extended with a 3-h EEG and a consultation with an epilepsy expert. Information on epilepsy and AD were collected and analyzed. Results: Among the 25 included patients, 10 (40%) were classified as epileptic. Seizure types were tonic-clonic (25%), typical temporal seizures (25%), myoclonus (25%), focal extra-temporal seizures (8%), and other seizure types (17%). AD-E patients had a significant lower MMSE (15.3±8.4 AD-E versus 22.1±5.1 AD-NE, p = 0.036) and a lower autonomy (IADL 4.1±2.7 AD-E versus 6.4±1.9 AD-NE, p = 0.046) at AD diagnosis with comparable ages between AD-E and AD-NE. Epileptic patients seemed to present a faster cognitive decline ([ΔMMSE per year 1.7±1.3 AD-E versus 0.9±1.4 AD-NE; p = 0.09). All patients with severe cognitive impairment (MMSE ≤ 10) had an epileptic comorbidity. Conclusion: Epilepsy is a frequent comorbidity in EOAD patients, with a percentage of 40%in our study. This comorbidity may be associated with a severe form of EOAD. The role of epilepsy in the acceleration of cognitive decline and the positive impact of antiepileptic drugs on cognition need further research. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|